| T-pa | acute myocardial infarction, in late reperfusion | vs placebo | - | - | - | NS | NS | - | NS | - | - | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | Cardiovascular death | no data | | Heart failure | no data | | Long term death | 1.26 [0.52 3.07] | p=1.00 | 0 | 197 | 1 | TAMI 6, | | Major bleeding | 0.79 [0.17 3.62] | p=1.00 | 0 | 197 | 1 | TAMI 6, | | Haemmorhagic stroke | no data | | short term death | 0.91 [0.79 1.05] | p=1.00 | 0 | 5908 | 2 | LATE, TAMI 6, | | Deaths or MI | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | reinfarction | 0.63 [0.15 2.72] | p=1.00 | 0 | 197 | 1 | TAMI 6, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| LATE, 1993 | intravenous alteplase (100 mg over 3 h) | placebo | patients with symptoms and electrocardiographic criteria consistent with AMI between 6 and 24 h from symptom onset | | TAMI 6, 1992 | tissue-type plasminogen activator 100 mg over 2 hours | placebo | patients with 6 to 24 hours of symptoms and ECG ST elevation |
|
| PTCA | acute myocardial infarction, in late reperfusion | vs no PTCA | NS | - | NS | - | - | - | - | NS | - | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.99 [0.74 1.32] | p=1.00 | 0 | 2607 | 6 | TOMIIS, Horie et al, TOAT, DECOPI, Silva et al, OAT, | | Cardiovascular death | no data | | Heart failure | 0.83 [0.56 1.21] | p=1.00 | 0 | 2607 | 6 | TOMIIS, Horie et al, TOAT, DECOPI, Silva et al, OAT, | | Long term death | no data | | Major bleeding | no data | | Haemmorhagic stroke | no data | | short term death | no data | | Deaths or MI | 1.14 [0.89 1.45] | p=1.00 | 0 | 2607 | 6 | TOMIIS, Horie et al, TOAT, DECOPI, Silva et al, OAT, | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | 1.26 [0.88 1.82] | p=1.00 | 0 | 2607 | 6 | TOMIIS, Horie et al, TOAT, DECOPI, Silva et al, OAT, | | reinfarction | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| TOMIIS, 1994 | late PTCA | no PTCA | patients with a recent, first Q-wave myocardial infarction and an occluded infarct-related coronary artery | | Horie et al, 1998 | late revascularization by primary PTCA | no PTCA | patients with initial Q-wave anterior myocardial infarction >24 hours after onset | | TOAT, 2002 | late revascularization (late intervention and stent to the LAD + medical therapy) | conservative therapy (medical therapy) | symptom-free patients after acute myocardial infarction | | DECOPI, 2004 | percutaneous revascularization carried out 2-15 days after symptom onset | medical treatment | patients with a first Q-wave myocardial infarction and an occluded infarct vessel | | Silva et al, 2005 | percutaneous coronary intervention | conservative therapy (no-PCI) | patients with occluded infarct-related artery between 12 h and 14 days post-anterior MI were | | OAT, 2006 | routine PCI and stenting | optimal medical therapy alone | stable patients who had total occlusion of the infarct-related artery 3 to 28 days after myocardial infarction and who met a high-risk criterion ( | | TOSCA-2, 2006 | PCI with stenting | optimal medical therapy alone | patients with an occluded native infarct-related artery 3 to 28 days after MI |
|
